The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition

by Muhammad Saad, Umut Gomceli, Pranav Ravi, Andrisael G Lacoste, Neil Shah, Timothy J Vittorio
Published 2018-11-01

Ketoacidosis without significantly hyperglycaemia - is it possible?

by Michał Budzyński, Joanna Pekar, Justyna Magdalena Skolarczyk, Monika Tadla, Katarzyna Skórzyńska-Dziduszko
Published 2017-06-01

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis

by Hang-Long Li, Gregory-Y. H. Lip, Qi Feng, Yue Fei, Yi-Kei Tse, Mei-zhen Wu, Qing-wen Ren, Hung-Fat Tse, Bernard-M. Y. Cheung, Kai-Hang Yiu
Published 2021-05-01

Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by...

by Kawarasaki S, Sawazaki H, Iijima H, Ng SP, Kwon J, Mohri S, Iwase M, Jheng HF, Takahashi H, Nomura W, Inoue K, Kawada T, Goto T
Published 2020-11-01

Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completio...

by Milton Packer
Published 2019-10-01

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives

by Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi, Andrea Giaccari
Published 2019-02-01

Canagliflozin for Japanese patients with chronic heart failure and type II diabetes

by Akira Sezai, Hisakuni Sekino, Satoshi Unosawa, Makoto Taoka, Shunji Osaka, Masashi Tanaka
Published 2019-06-01

SGLT-2 Inhibitors: Are They a Promising Treatment Option in T2DM Patients with NAFLD?

by Dimitrios Patoulias
Published 2018-04-01

Sodium–glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions

by D'Elia JA, Segal AR, Bayliss GP, Weinrauch LA
Published 2017-06-01

Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice

by Hideyuki Okuma, Kentaro Mori, Suguru Nakamura, Tetsuo Sekine, Yoshihiro Ogawa, Kyoichiro Tsuchiya
Published 2021-07-01

Interaction Between Non-Insulin Glucose-Lowering Medication and Exercise in Type 2 Diabetes Mellitus – New Findings on SGLT2 Inhibitors

by Christian Brinkmann, Christian Brinkmann
Published 2021-07-01

Influence of sodium glucose co-transporter 2 inhibitors on fatty liver index parameters in type 2 diabetes mellitus

by Mohammed Ali Gameil, Mohammed Shereif Abdelgawad, Monir Hussein Bahgat, Ahmed Hassan Elsebaie, Rehab Elsayed Marzouk
Published 2020-08-01

Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial

by Jens Christian Laursen, MD, Niels Søndergaard-Heinrich, MD, Joana Mendes Lopes de Melo, PhD, Bryan Haddock, PhD, Ida Kirstine Bull Rasmussen, MD, Farzaneh Safavimanesh, PhD, Christian Stevns Hansen, PhD, Joachim Størling, PhD, Henrik Bo Wiberg Larsson, DMSc, Per-Henrik Groop, DMSc, Marie Frimodt-Møller, PhD, Ulrik Bjørn Andersen, MD, Peter Rossing, DMSc
Published 2021-07-01

Sodium glucose co-transporter 2 inhibitors in heart failure therapy

by Yüksel Çavuşoğlu, Hakan Altay, Avivit Cahn, Ahmet Celik, Serafettin Demir, Barış Kılıçaslan, Sanem Nalbantgil, Itamar Raz, Ahmet Temizhan, Özlem Yıldırımtürk, Mehmet Birhan Yılmaz
Published 2020-04-01

Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review

by Koichiro Matsumura, Tetsuro Sugiura
Published 2019-11-01

The latest recommendations of the Polish Diabetes Association and the American Diabetes Association in the treatment of diabetes with modern drugs

by Szymon Marosz, Aleksandra Borkowska, Paulina Mikulska, Katarzyna Borkowska, Jolanta Kowieska
Published 2020-09-01

SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans

by Heeyoung Chae, Robert Augustin, Eva Gatineau, Eric Mayoux, Mohammed Bensellam, Nancy Antoine, Firas Khattab, Bao-Khanh Lai, Davide Brusa, Birgit Stierstorfer, Holger Klein, Bilal Singh, Lucie Ruiz, Michael Pieper, Michael Mark, Pedro L. Herrera, Fiona M. Gribble, Frank Reimann, Anne Wojtusciszyn, Christophe Broca, Nano Rita, Lorenzo Piemonti, Patrick Gilon
Published 2020-12-01

SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin

by Santosh Kumar Singh, A K Gupta
Published 2014-01-01

Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus

by Shusuke Yagi, Yukina Hirata, Takayuki Ise, Kenya Kusunose, Hirotsugu Yamada, Daiju Fukuda, Hotimah Masdan Salim, Gulinu Maimaituxun, Susumu Nishio, Yuriko Takagawa, Saori Hama, Tomomi Matsuura, Koji Yamaguchi, Takeshi Tobiume, Takeshi Soeki, Tetsuzo Wakatsuki, Ken-ichi Aihara, Masashi Akaike, Michio Shimabukuro, Masataka Sata
Published 2017-10-01

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes

by Derosa G, Maffioli P
Published 2018-09-01